Flattening of a treatment-resistant retinal pigment epithelial detachment after a single intravitreal injection of ziv-aflibercept
Conclusion: Intravitreal ziv-aflibercept safely and effectively improved a treatment-resistant PED. Intravitreal ziv-aflibercept could become a treatment option for neovascular age-related macular degeneration in countries where aflibercept (Eylea) is not available or its cost is prohibitive, but further studies are necessary to establish efficacy and safety. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - March 18, 2017 Category: Opthalmology Tags: Case Report Source Type: research

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
mp; M Călugăru (Source: Eye)
Source: Eye - March 17, 2017 Category: Opthalmology Authors: D C ălugăru Source Type: research

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
ource: Eye)
Source: Eye - March 17, 2017 Category: Opthalmology Authors: D C ă lug ă ru M C ă lug ă ru Source Type: research

Effect of Syringe Design on the Accuracy and Precision of Intravitreal Injections of Anti-VEGF Agents.
Abstract PURPOSE: To evaluate the accuracy and precision of different syringe designs for intravitreal injection of anti-VEGF agents. METHODS: Volume output was measured from three syringe designs-1) 1.0 mL tuberculin syringe, 2) 1.0 mL syringe with low dead space plunger, and 3) 0.5 mL low-volume syringe-to deliver 50 µL of bevacizumab, ranibizumab, or aflibercept, each repeated four times by three different physicians for 108 total simulated injections. Volume output was calculated from difference in syringe weight before and after expelling the drug. Accuracy was determined by mean absolute percentag...
Source: Current Eye Research - March 17, 2017 Category: Opthalmology Authors: Moisseiev E, Rudell J, Tieu EV, Yiu G Tags: Curr Eye Res Source Type: research

Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema
The short-term effects of intravitreal ranibizumab (IVR) on diabetic macular edema (DME) remains unclear. We assessed the short-term effects of IVR on DME. (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - March 14, 2017 Category: Opthalmology Authors: Yoshiro Minami, Taiji Nagaoka, Akihiro Ishibazawa and Akitoshi Yoshida Source Type: research

Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial
We read with interest the article by Beaulieu and colleagues1 regarding patient-centered outcomes in the treatment of proliferative diabetic retinopathy (PDR). Both proliferative and advanced nonproliferative retinopathy may cause significant loss of peripheral vision and visual acuity (particularly in dim light situations or night driving). New therapeutic options are available to treat and effectively manage diabetic retinopathy and help enhance quality of life.2 However, aggressive use of modern treatment for diabetic retinopathy potentially would improve vision in most patients, but it is a challenge that many patients...
Source: American Journal of Ophthalmology - March 13, 2017 Category: Opthalmology Authors: Ediriweera Desapriya, Parisa Khoshpouri, Abdulwahab Al-Isa Tags: Correspondence Source Type: research

Reply
We thank Drs Desapriya, Khoshpouri, and Al-Isa for their comments on our Diabetic Retinopathy Clinical Research Network (DRCR.net) report on patient-centered and driving-related outcomes from the DRCR.net's Protocol S, a randomized clinical trial of ranibizumab vs panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR).1 Beyond their comments unrelated specifically to our findings in their first paragraph, they indicated in their second paragraph that differences in work productivity and driving-related outcomes slightly favored the ranibizumab group over the PRP group, but that the difference was no...
Source: American Journal of Ophthalmology - March 12, 2017 Category: Opthalmology Authors: Wesley T. Beaulieu, Neil M. Bressler, Jeffrey G. Gross, Diabetic Retinopathy Clinical Research Network Tags: Correspondence Source Type: research

Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial
We thank Drs Desapriya, Khoshpouri, and Al-Isa for their comments on our Diabetic Retinopathy Clinical Research Network (DRCR.net) report on patient-centered and driving-related outcomes from the DRCR.net's Protocol S, a randomized clinical trial of ranibizumab vs panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR).1 Beyond their comments unrelated specifically to our findings in their first paragraph, they indicated in their second paragraph that differences in work productivity and driving-related outcomes slightly favored the ranibizumab group over the PRP group, but that the difference was no...
Source: American Journal of Ophthalmology - March 12, 2017 Category: Opthalmology Authors: Wesley T. Beaulieu, Neil M. Bressler, Jeffrey G. Gross, Diabetic Retinopathy Clinical Research Network Tags: Correspondence Source Type: research

Early and Long-term Responses to Anti –Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
In an important study, Gonzales and associates1 analyze the 3-year study data from patients in the Diabetic Retinopathy Clinical Research Network's Protocol I study2 who were treated with ranibizumab plus prompt or deferred laser and provided an observed best-corrected visual acuity (BCVA) reading at 12  weeks. The analysis reveals that after 3-monthly ranibizumab injections plus prompt focal/grid laser treatment in part of the eyes, 40% (135/340) of diabetic macular edema (DME) eyes showed at best only limited BCVA gain ( (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - March 12, 2017 Category: Opthalmology Authors: Avinoam Ophir Tags: Correspondence Source Type: research

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
Publication date: Available online 8 March 2017 Source:Saudi Journal of Ophthalmology Author(s): Tariq Al-Debasi, Abdulkareem Al-Bekairy, Abdulmalik Al-Katheri, Shmeylan Al Harbia, Mahmoud Mansour In order to evaluate the effect of topical and subconjunctival anti-vascular endothelial growth factor (anti-VEGF) therapy; Ranibizumab, Bevacizumab and Aflibercept as a therapy for corneal neovascularization (NV) treatment, the aim of this study is to review all data related to some of anti-VEGF as a promising therapies for corneal NV treatment. Corneal NV is a dangerous condition leading to a marked reduction in vision due to ...
Source: Saudi Journal of Ophthalmology - March 9, 2017 Category: Opthalmology Source Type: research

Intravitreal PRN ranibizumab treatment for macular edemadue to branch retinal vein occlusion.
Authors: Çakmak HB, Arikan Yorgun M, Toklu Y, Mutlu M Abstract BACKGROUND/AIM: To evaluate the effect of intravitreal pro re nata (PRN) ranibizumab treatment from the start on the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) in macular edema (ME) due to branch retinal vein occlusion (BRVO). MATERIALS AND METHODS: Patients with ME secondary to BRVO, who were treated on a PRN basis after a single intravitreal ranibizumab injection, were retrospectively evaluated. The main outcome measures were changes in BCVA and CRT as measured by optical coherence tomography. RESULTS: T...
Source: Turkish Journal of Medical Sciences - March 8, 2017 Category: Journals (General) Tags: Turk J Med Sci Source Type: research

The Clinical Importance of Changes in Diabetic Retinopathy Severity Score
To investigate the clinical importance of changes in diabetic retinopathy severity score (DRSS) in patients with diabetic macular edema (DME) treated with intravitreal ranibizumab. (Source: Ophthalmology)
Source: Ophthalmology - March 8, 2017 Category: Opthalmology Authors: Michael S. Ip, Jiameng Zhang, Jason S. Ehrlich Source Type: research

Intravitreal Anti-Vascular Endothelial Growth Factor for Macular Edema due to Complex Retinal Arterial Macroaneurysms
Conclusion: RAM can manifest with heterogeneous findings. Intravitreal anti-VEGF therapy with or without laser photocoagulation may be an effective treatment option in cases of macular edema due to RAM. Aflibercept and ranibizumab seem to be a potent anti-VEGF therapy for RAM. Individualized patient care is needed.Case Rep Ophthalmol 2017;8:141 –147 (Source: Case Reports in Ophthalmology)
Source: Case Reports in Ophthalmology - March 7, 2017 Category: Opthalmology Source Type: research

Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion
Abstract AimTo evaluate the role of small cystic macular changes as a prognostic factor for the recurrence of macular oedema (ME) in patients with branch retinal vein occlusion (BRVO) treated with anti‐VEGF drugs. MethodsWe performed retrospective chart analysis of 116 patients treated with intravitreal injection of ranibizumab (IVR) or bevacizumab (IVB) for ME secondary to BRVO. At the baseline and monthly follow‐up visits over a period of 12 months, a comprehensive ophthalmologic examination including best‐corrected visual acuity (BCVA) and volume scan of macula using Spectral domain optical coherence tomograp...
Source: Acta Ophthalmologica - March 7, 2017 Category: Opthalmology Authors: Eric Tilgner, Maiara Dalcegio Favretto, Maria Tuisl, Peter Wiedemann, Matus Rehak Tags: Original Article Source Type: research

Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular oedema.
Abstract BACKGROUND/AIMS: To investigate the relations between aqueous humour levels of cytokines/growth factors and treatment response to intravitreal ranibizumab (IVR) for diabetic macular oedema (DME) METHODS: Sixty-eight eyes of 68 patients with treatment-naïve centre-involved DME, central macular thickness (CMT) greater than 400 μm and visual acuity (VA) worse than logMAR 0.3 were recruited. Each patient received monthly IVR injection (0.5 mg/0.05 mL) until CMT was reduced to below 300 μm. Additional IVR was given to maintain CMT below 300 μm during the clinical course of 6 months wi...
Source: The British Journal of Ophthalmology - March 7, 2017 Category: Opthalmology Authors: Shimura M, Yasuda K, Motohashi R, Kotake O, Noma H Tags: Br J Ophthalmol Source Type: research

Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.
CONCLUSION: Even so ranibizumab treatment is an effective therapy for ROP in early period, close monitoring after injection is necessary due to the high incidence of recurrence. In addition, questions remain regarding the systemic safety of ranibizumab. Further studies are needed to study the systemic and ocular side effects of ranibizumab. PMID: 28277877 [PubMed - as supplied by publisher] (Source: Cutaneous and Ocular Toxicology)
Source: Cutaneous and Ocular Toxicology - March 6, 2017 Category: Toxicology Authors: Alyamaç Sukgen E, Koçluk Y Tags: Cutan Ocul Toxicol Source Type: research

Using Off-Label Intravitreous Bevacizumab for Diabetic Macular Edema
To the Editor Based on the results of the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial, Ross and colleagues have conducted a pharmacoeconomic study in which the cost-effectiveness of aflibercept, ranibizumab, and off-label bevacizumab was estimated for patients with diabetic macular edema. Defining the place in therapy for these treatments took into account that off-label bevacizumab costs 31 and 20 times less than aflibercept and ranibizumab, respectively, while differences in efficacy are modest. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - March 1, 2017 Category: Opthalmology Source Type: research

Using Off-Label Intravitreous Bevacizumab for Diabetic Macular Edema
To the Editor We would like to comment on the implications to clinical practice of an analysis by Ross et al examining the cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for the treatment of diabetic macular edema (DME) that was recently published inJAMA Ophthalmology. Protocol T demonstrated aflibercept to be superior to bevacizumab in visual acuity outcomes, especially among patients with at least moderate vision loss ( ≤20/50), anatomic improvement at all time points regardless of presenting visual acuity, and the need for adjunctive macular laser photocoagulation. The retina community has incorporat...
Source: JAMA Ophthalmology - March 1, 2017 Category: Opthalmology Source Type: research

Head ‐to‐head comparison of ranibizumab PRN versus single‐dose dexamethasone for branch retinal vein occlusion (COMRADE‐B)
ConclusionRanibizumab PRN resulted in greater visual acuity (VA) gains in macular oedema following BRVO compared with single‐dose dexamethasone over a 6‐month study period, observed from month 3, when administered according to their European label. In clinical practice, retreatment with dexamethasone may be required prior to this point. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - March 1, 2017 Category: Opthalmology Authors: Lars ‐Olof Hattenbach, Nicolas Feltgen, Thomas Bertelmann, Steffen Schmitz‐Valckenberg, Hüsnü Berk, Nicole Eter, Gabriele E. Lang, Matus Rehak, Simon R. Taylor, Armin Wolf, Claudia Weiss, Eva‐Maria Paulus, Amelie Pielen, Hans Hoerauf, Tags: Original Article Source Type: research

Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
S Baillif, S Regnier, A Skelly, N Yu& A Sodi (Source: Eye)
Source: Eye - February 24, 2017 Category: Opthalmology Authors: S Nghiem-Buffet Source Type: research

Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
p; A Sodi (Source: Eye)
Source: Eye - February 24, 2017 Category: Opthalmology Authors: S Nghiem-Buffet S Baillif S Regnier A Skelly N Yu A Sodi Source Type: research

TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: One-Year Results
Purpose: To investigate the efficacy of a treat-and-extend regimen (TER) using ranibizumab to treat polypoidal choroidal vasculopathy (PCV). Methods: We retrospectively reviewed the medical records of 29 patients with PCV, who had been treated with a TER for 1 year. The primary outcome was the proportion of eyes that did not lose ≥3 best-corrected visual acuity (BCVA) lines. The number of intravitreal injections and recurrences as well as the maximum treatment interval without recurrence were analyzed. Results: The mean BCVA improved from 0.64 ± 0.42 logMAR (median, 20/80) at baseline to 0.30 ± 0.31 logM...
Source: RETINA - February 23, 2017 Category: Opthalmology Tags: Original Study Source Type: research

EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB: A Secondary Analysis of Trial Data
Purpose: Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion. The authors also assessed detectability of response to treatment. Methods: The authors used data from 325 participants in the CRUISE study, which included measurement of time-domain CRT and BCVA at baseline, 1 week, 1 month, and 6 months postrandomization. Analysis of covariance models were fitted to assess clinical validity, and distributions of change were constructed to ...
Source: RETINA - February 23, 2017 Category: Opthalmology Tags: Original Study Source Type: research

The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain.
Authors: Navarro-Navarro A, Salom D, Martínez-Toldos JJ, Udaondo P, Fernández-Martínez C, Gutiérrez-Arias L, Hervás A, Rodrigo R PMID: 28215618 [PubMed - as supplied by publisher] (Source: Archivos de la Sociedad Espanola de Oftalmologia)
Source: Archivos de la Sociedad Espanola de Oftalmologia - February 23, 2017 Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research

Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et  al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761)
We congratulate the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Writing Committee for publishing the 5-year results of the CATT trial of bevacizumab and ranibizumab for neovascular age-related macular degeneration.1 The CATT long-term study highlighted an average of 3.3 letters lost 5 years after starting treatment compared with 0.7 letters lost in our study,2 where a loss of just 2.7 letters was observed at 7 years. (Source: Ophthalmology)
Source: Ophthalmology - February 17, 2017 Category: Opthalmology Authors: Mark C. Gillies, Vincent Daien, Vuong Nguyen, Daniel Barthelmes Tags: Correspondence Source Type: research

Reply
We appreciate the interest of Dr Tornambe in our article and welcome the opportunity to respond. The author correctly notes that the 1-year results of our comparative effectiveness study of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema showed that in eyes with baseline vision worse than 20/40, aflibercept, on average, resulted in greater improvement in visual acuity from baseline (+19 letters) compared with the other 2 agents (+12 for bevacizumab [P (Source: Ophthalmology)
Source: Ophthalmology - February 17, 2017 Category: Opthalmology Authors: John A. Wells, Adam R. Glassman, Lee M. Jampol, Allison Ayala, Neil M. Bressler Tags: Correspondence Source Type: research

Re: Wells et  al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1358)
Physicians are taught it is important to temper initial enthusiasm with the test of time. This lesson was illustrated in the paper by Wells et  al.1 The 1-year post hoc analysis showed that, for the group of eyes presenting with diabetic macular edema (DME) with worse than 20/40 visual acuity, aflibercept was superior to ranibizumab and bevacizumab; however, this article, which evaluates the 2-year data, indicates there is no difference in visual outcomes between aflibercept and ranibizumab. The authors also point out that the small relative differences in visual acuity at 2 years, among all three drugs, rai...
Source: Ophthalmology - February 17, 2017 Category: Opthalmology Authors: Paul Tornambe Tags: Correspondence Source Type: research

6-Year Results of CNV Secondary to Pathological Myopia Treated with Ranibizumab.
Conclusion After considerable initial improvement in visual acuity, the initial gain was maintained by a strict PRN regimen for the observation and treatment of patients with neovascular membranes secondary to pathological myopia. The number of injections needed to achieve stable visual acuity was lower than with other diseases that respond to anti-VEGF. PMID: 28192841 [PubMed - as supplied by publisher] (Source: Klinische Monatsblatter fur Augenheilkunde)
Source: Klinische Monatsblatter fur Augenheilkunde - February 15, 2017 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

Difficulties in the management of retinal capillary haemangiomas associated with von Hippel Lindau disease.
DISCUSSION: VHL syndrome causes a complex ocular disease with a difficult diagnosis that requires early treatment of the RCH in order to modify its visual prognosis. PMID: 28169069 [PubMed - as supplied by publisher] (Source: Archivos de la Sociedad Espanola de Oftalmologia)
Source: Archivos de la Sociedad Espanola de Oftalmologia - February 10, 2017 Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research

The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
ConclusionThis study used novel repeated-measures NMA to synthesize efficacy results when treatment effects were reported at multiple follow-up times. This repeated-measures NMA suggests that treating patients with the ranibizumab T&E regimen yields similar effectiveness compared to other approved ranibizumab and aflibercept dosing regimens for nAMD treatment.Funding: Novartis Pharmaceuticals UK Ltd, Surrey, UK. (Source: Advances in Therapy)
Source: Advances in Therapy - February 10, 2017 Category: Drugs & Pharmacology Source Type: research

Development of a Sustainable Release System for a Ranibizumab Biosimilar Using Poly(lactic-co-glycolic acid) Biodegradable Polymer-Based Microparticles as a Platform.
Abstract Ranibizumab is a humanized monoclonal antibody fragment against vascular endothelial growth factor (VEGF)-A and is widely used to treat age-related macular degeneration (AMD) caused by angiogenesis. Ranibizumab has a short half-life in the eye due to its low molecular weight and susceptibility to proteolysis. Monthly intravitreal injection of a large amount of ranibizumab formulation is a burden for both patients and medical staff. We therefore sought to develop a sustainable release system for treating the eye with ranibizumab using a drug carrier. A ranibizumab biosimilar (RB) was incorporated into micr...
Source: Biological and Pharmaceutical Bulletin - February 7, 2017 Category: Drugs & Pharmacology Authors: Tanetsugu Y, Tagami T, Terukina T, Ogawa T, Ohta M, Ozeki T Tags: Biol Pharm Bull Source Type: research

Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema
AbstractPurposeTo compare the efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema (DME).Study designA retrospective, nonrandomized, and comparative study.MethodsFrom May 2013 to March 2016, 148 eyes of 148 patients with treatment-na ïve center-involving DME were reviewed in one institution. Forty-six eyes underwent prior vitrectomy at least 3 months ago, and 102 eyes did not receive any vitrectomy. Three monthly then PRN intravitreal ranibizumab treatments were performed in all the patients with monthly follow-up for 6 month s. Primary outcome mea...
Source: International Ophthalmology - February 7, 2017 Category: Opthalmology Source Type: research

Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab
To compare rates and identify predictive factors for events that represent worsening of proliferative diabetic retinopathy (PDR) in eyes treated with panretinal photocoagulation (PRP) or ranibizumab. (Source: Ophthalmology)
Source: Ophthalmology - February 1, 2017 Category: Opthalmology Authors: Susan B. Bressler, Wesley T. Beaulieu, Adam R. Glassman, Jeffrey G. Gross, Lee M. Jampol, Michele Melia, Mark A. Peters, Michael E. Rauser, Diabetic Retinopathy Clinical Research Network Source Type: research

Switching from pro re nata to treat ‐and‐extend regimen improves visual acuity in patients with neovascular age‐related macular degeneration
ConclusionEven after prolonged treatment and a high number of intravitreal injections, switching AMD patients from a PRN regimen to a strict TAE regimen significantly improves visual acuity. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - January 31, 2017 Category: Opthalmology Authors: Line Kvannli, J ørgen Krohn Tags: Original Article Source Type: research

A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
AbstractIntroductionNeovascular age-related macular degeneration (nAMD) is the leading cause of vision loss among persons aged 65  years and older. Anti-vascular endothelial growth factor (anti-VEGF) treatment is the recommended standard of care. The current study compares the effectiveness of ranibizumab in routine clinical practice in two countries that generally apply two different treatment regimens, treat-and-extend (T&E) in Australia or pro re nata (PRN) in the UK.MethodsThis retrospective, comparative, non-randomised cohort study is based on patients ’ data from electronic medical record (EMR) databas...
Source: Advances in Therapy - January 31, 2017 Category: Drugs & Pharmacology Source Type: research

Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
CONCLUSION: IVB, IVR and LP are options that can successfully treat ROP. Myopia was observed to be the main refractive error in all treatment groups. Vascularization of the retina was completed later in the IVB group than in the IVR group. PMID: 28128986 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - January 27, 2017 Category: Opthalmology Authors: Kabataş EU, Kurtul BE, Altıaylık Özer P, Kabataş N Tags: Curr Eye Res Source Type: research

[Strategies of Intravitreal Injections with Anti-VEGF: "Pro re Nata versus Treat and Extend"].
[Strategies of Intravitreal Injections with Anti-VEGF: "Pro re Nata versus Treat and Extend"]. Klin Monbl Augenheilkd. 2017 Jan 23;: Authors: Hufendiek K, Pielen A, Framme C Abstract The goal of this report is to provide a review on different strategies for the use of pro re nata (PRN) and treat and extend (T&E) regimens with intravitreal anti-VEGF agents (bevacizumab, ranibizumab or aflibercept) in patients with retinal diseases such as neovascular AMD, diabetic macular oedema and macular oedema due to retinal vein occlusion. The main focus is to present the effectiveness and visual outc...
Source: Klinische Monatsblatter fur Augenheilkunde - January 26, 2017 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

Cardiovascular involvement in patients with diabetic macular oedema treated with intravitreal ranibizumab in routine clinical practice.
CONCLUSION: In our experience it seems that the intravitreal ranibizumab in diabetic macular oedema could be a safe alternative in patients with a history of stroke and myocardial infarction. PMID: 28110972 [PubMed - as supplied by publisher] (Source: Archivos de la Sociedad Espanola de Oftalmologia)
Source: Archivos de la Sociedad Espanola de Oftalmologia - January 25, 2017 Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research

Reduced-fluence photodynamic therapy and anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy in an Indian population
Conclusions: RFPDT with anti-VEGF is safe and effective treatment with polyp regression and vision improvement in 80% of cases, without any complication of subretinal hemorrhage/vitreous hemorrhage. (Source: Indian Journal of Ophthalmology)
Source: Indian Journal of Ophthalmology - January 23, 2017 Category: Opthalmology Authors: Parveen Sen Muna Bhende Ramya Sachidanandam Nishat Bansal Tarun Sharma Source Type: research

Effect of anti-VEGF drugs combined with photodynamic therapy in the treatment of age-related macular degeneration.
Authors: Dong Y, Wan G, Yan P, Chen Y, Wang W, Peng G Abstract We analyzed the effects of anti-vascular endothelial growth factor (VEGF) drugs combined with photodynamic therapy (PDT) in the treatment of age-related macular degeneration (AMD). Ninety-six cases (192 eyes) of AMD were included in this study and randomly divided into the observation group and control group (n=48 cases per group). The control group was administered the treatment of Lucentis intravitreal injection alone and the observation group was administered Lucentis combined with PDT. The therapeutic effects were compared. The best corrected visual...
Source: Experimental and Therapeutic Medicine - January 22, 2017 Category: Journals (General) Tags: Exp Ther Med Source Type: research

Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia
ConclusionsSRNVM development is a severe complication of type 2 IJT. Since the establishment of intravitreal anti-VEGF treatment laser coagulation and PDT have lost significance. Intravitreal anti-VEGF therapy seems to be safe and effective for the treatment of IJT-related SRNVM. Frequently multiple intravitreal injections are necessary for stabilisation. (Source: International Ophthalmology)
Source: International Ophthalmology - January 21, 2017 Category: Opthalmology Source Type: research

Functional-morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab
Conclusions These findings suggest that the aqueous flare is associated with inflammatory factors/cytokines, and that the change of the aqueous flare value may influence the long-term prognosis in patients with BRVO receiving IRI therapy for macular oedema. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - January 20, 2017 Category: Opthalmology Authors: Noma, H., Mimura, T., Yasuda, K., Shimura, M. Tags: Retina Original articles - Clinical science Source Type: research

Intraocular Cytokines and Their Correlations with Clinical Parameters in Patients with Myopic Choroidal Neovascularization
Conclusion: The decrease in VEGF levels accompanied by imbalance of other cytokines may suggest additional mCNV development pathways.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - January 19, 2017 Category: Opthalmology Source Type: research

Response of vascular pigment epithelium detachment due to age ‐related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study
ConclusionSerous vascular PED lesions showed an improvement regarding BCVA and morphologic characteristics unless an RPE tear occurred. In fPED lesions, a functional and morphological stabilization was observed. Monthly ranibizumab injections are an effective treatment regarding the resorption of subretinal fluid in vPED due to AMD. Patients should be screened for the presence of morphologic risk factors for RPE tear development before and during treatment. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - January 13, 2017 Category: Opthalmology Authors: Christoph R. Clemens, Armin Wolf, Florian Alten, Carolin Milojcic, Peter Heiduschka, Nicole Eter Tags: Original Article Source Type: research

Assessment of Corneal Sensation, Innervation and Retinal Nerve Fiber Layer in Patients Treated with Multiple Intravitreal Ranibizumab Injections
ConclusionsMultiple intravitreal injections of ranibizumab seem to have no harmful effects on corneal sensitivity, innervation and peripapillary RNFL thickness in patients with AMD. (Source: PLoS One)
Source: PLoS One - January 13, 2017 Category: Biomedical Science Authors: Gulfidan Bitirgen Source Type: research

Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage.
Authors: Xu Y, Kang X, Zhang Q, Huang Q, Lv J, Zhao P Abstract To investigate the efficacy of intravitreal ranibizumab (IVR) combined with laser photocoagulation for aggressive posterior retinopathy of prematurity (AP-ROP) patients with vitreous hemorrhage, we conducted a retrospective observational case series study. A total of 37 eyes of 20 patients' medical records were reviewed. Patients first received IVR (0.25 mg/0.025 mL) and later photocoagulation. The mean postconceptual age of injection was 34.6 ± 1.4 weeks, and the mean follow-up period was 39.3 ± 8.3 weeks. During the follow-...
Source: Journal of Ophthalmology - January 12, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration
R Rasier, C Ciftci, O Artunay, A Kockar, H Bahcecioglu& E Yuzbasioglu (Source: Eye)
Source: Eye - January 6, 2017 Category: Opthalmology Authors: A Sengul Source Type: research

Efficacy of aflibercept on exudative age-related macular degeneration in patients exhibiting complete ranibizumab resistance and tachyphylaxis
Conclusions: Although treatment with aflibercept yielded generally positive anatomical results in both groups, no significant increase in visual acuity was achieved.RESUMO Objetivo: O presente estudo comparou a efic ácia do aflibercept na degeneração macular neovascular relacionada à idade (NV-AMD) com de resistência completa ao ranibizumab e taquifilaxia ao ranibizumab. Método: Quarenta e quatro olhos de 38 pacientes com degeneração macular neovascular relacionada à idade foram inscritos. Eles foram divididos em dois grupos: grupo de resistência completa ...
Source: Arquivos Brasileiros de Oftalmologia - January 5, 2017 Category: Opthalmology Source Type: research

Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema
ABSTRACT Purpose: To investigate the influence of the epiretinal membrane (ERM) on intravitreal ranibizumab (IVR) therapy for diabetic macular edema (DME). Methods: This retrospective study included 56 eyes of 48 patients with DME divided into two groups: the DME with ERM (study) and only DME (control) groups. Changes in the central macular thickness (CMT) and best-corrected visual acuity (BCVA) were evaluated. Results: In the study group, although the CMT was significantly reduced following the first injection (p
Source: Arquivos Brasileiros de Oftalmologia - January 5, 2017 Category: Opthalmology Source Type: research

Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion.
Conclusion. Approximately 30% of patients showed low response to ranibizumab after the loading phase and after 1 year of treatment. Two-thirds of patients that were low-responders after the loading phase remained low-responders after 1 year. PMID: 28044102 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - January 5, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research